Welcome
Health Law & Business News

Chinese Vaccine Approved for Human Testing at Virus Epicenter

March 18, 2020, 6:07 AM

CanSino Biologics Inc. said it received Chinese regulatory approval to start human trials of a vaccine against the novel coronavirus, another example of a potential weapon against the illness being fast-tracked for testing as the global death toll escalates and nations impose lockdowns on their citizens.

The vaccine, co-developed by the Hong Kong-listed company and China’s Academy of Military Medical Sciences, will undergo clinical trials in Wuhan, CanSino Biologics said in a statement to the Hong Kong Stock Exchange on Wednesday. Wuhan is the epicenter for the pandemic that has spread to all corners of the planet, infecting more than...

To read the full article log in. To learn more about a subscription click here.